NEW YORK – Seegene said Tuesday that it has signed a technology sharing agreement with Spanish diagnostics firm Werfen under which the firms will establish a new company called Werfen-Seegene in Spain.
Financial terms of the agreement were not disclosed.
The new firm "will combine Werfen's extensive business experience with Seegene's leading syndromic product development and production capabilities," Jong-Yoon Chun, CEO and founder of South Korean firm Seegene, said in a statement.
"Over the past decade, our collaboration with Seegene has showcased the significant impact of their syndromic PCR diagnostic tests on healthcare," said Werfen CEO Carlos Pascual. "We are excited to leverage Seegene's unparalleled technology and manufacturing expertise to develop products tailored for the Spanish and Portuguese market, where there is a high demand for rapid product development due to the frequent emergence of new infectious diseases and viral mutations."
The partnership is part of a larger technology sharing business initiative by Seegene incorporating the Seoul-based firm's syndromic real-time PCR product development and manufacturing. Under these partnerships, the companies collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their local communities and fields, Seegene said.
The new Werfen-Seegene company will focus on diagnostics for infectious diseases, including antimicrobial and drug resistance, viral load, transplant monitoring, sexually transmitted infections, and emerging diseases.
Last year, Seegene expanded a partnership with Werfen to incorporate jointly developing syndromic qPCR assays and partnered with Microsoft to develop next-generation management and analytics for PCR data.